A377740 Stock Overview
Manufactures and sells in-vitro diagnostic animal medicines in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
BioNote, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩4,720.00 |
| 52 Week High | ₩6,400.00 |
| 52 Week Low | ₩3,865.00 |
| Beta | 0 |
| 11 Month Change | 2.50% |
| 3 Month Change | -3.97% |
| 1 Year Change | 12.38% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -55.68% |
Recent News & Updates
BioNote's (KRX:377740) Strong Earnings Are Of Good Quality
Nov 24
BioNote, Inc.'s (KRX:377740) 38% Price Boost Is Out Of Tune With Earnings
Aug 16There May Be Some Bright Spots In BioNote's (KRX:377740) Earnings
May 25Shareholder Returns
| A377740 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 0.4% | -3.5% | 2.5% |
| 1Y | 12.4% | 24.9% | -1.1% |
Return vs Industry: A377740 underperformed the KR Biotechs industry which returned 24.9% over the past year.
Return vs Market: A377740 exceeded the KR Market which returned -1.1% over the past year.
Price Volatility
| A377740 volatility | |
|---|---|
| A377740 Average Weekly Movement | 3.8% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 11.6% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A377740 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A377740's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | n/a | n/a | www.bionote.co.kr |
BioNote, Inc., manufactures and sells in-vitro diagnostic animal medicines in South Korea. It offers animal diagnostics products, such as fluorescence immunoassay, molecular diagnostics, clinical biochemistry, rapid immunoassay, and enzyme-linked immunosorbent assay products. The company also provides bio-content products, including rapid immunoassay for humans, human intermediate goods, and bio-contents reagents.
BioNote, Inc. Fundamentals Summary
| A377740 fundamental statistics | |
|---|---|
| Market cap | ₩481.70b |
| Earnings (TTM) | ₩40.35b |
| Revenue (TTM) | ₩99.81b |
11.9x
P/E Ratio4.8x
P/S RatioIs A377740 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A377740 income statement (TTM) | |
|---|---|
| Revenue | ₩99.81b |
| Cost of Revenue | ₩51.44b |
| Gross Profit | ₩48.36b |
| Other Expenses | ₩8.01b |
| Earnings | ₩40.35b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 395.42 |
| Gross Margin | 48.46% |
| Net Profit Margin | 40.43% |
| Debt/Equity Ratio | 0% |
How did A377740 perform over the long term?
See historical performance and comparison